Hcw biologics regains compliance with nasdaq capital market requirements

Miramar, fla., june 26, 2025 (globe newswire) -- hcw biologics inc. (“hcwb” or the “company”) (nasdaq: hcwb), a u.s.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from the nasdaq stock market llc (“nasdaq”) informing the company that it has regained compliance with the nasdaq capital market's minimum stockholders' equity requirement as required by nasdaq listing rule 5550(b)(1) (the “equity rule”).
HCWB Ratings Summary
HCWB Quant Ranking